BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8808649)

  • 1. Immunotherapy in neuromuscular disorders: current and future strategies.
    Drachman DB
    Muscle Nerve; 1996 Oct; 19(10):1239-51. PubMed ID: 8808649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects.
    Dalakas MC
    Ann Neurol; 1995 May; 37 Suppl 1():S2-13. PubMed ID: 8968213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review: the use of rituximab in neuromuscular diseases.
    Ibrahim H; Dimachkie MM; Shaibani A
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):91-102. PubMed ID: 21386778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in autoimmune neuromuscular disorders.
    Gold R; Dalakas MC; Toyka KV
    Lancet Neurol; 2003 Jan; 2(1):22-32. PubMed ID: 12849298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents.
    Farmakidis C; Dimachkie MM; Pasnoor M; Barohn RJ
    Muscle Nerve; 2020 Jan; 61(1):17-25. PubMed ID: 31531874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of the immune response in autoimmune demyelination.
    Oksenberg JR
    West J Med; 1994 Sep; 161(3):255-9. PubMed ID: 7975563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
    McIntosh KR; Linsley PS; Drachman DB
    Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From immunosuppression to immunomodulation: current principles and future strategies.
    Kovarik J
    Pathobiology; 2013; 80(6):275-81. PubMed ID: 24013771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel therapies for MG: Studies in animal models.
    Souroujon MC; Brenner T; Fuchs S
    Autoimmunity; 2010 Aug; 43(5-6):446-60. PubMed ID: 20298126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local delivery of cytokines by retrovirally transduced antigen-specific TCR+ hybridoma cells in experimental autoimmune encephalomyelitis.
    Dal Canto RA; Costa G; Shaw MD; Seroogy C; Nolan GP; Fathman CG
    Eur Cytokine Netw; 1998 Sep; 9(3 Suppl):83-91. PubMed ID: 9831193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.
    Adorini L
    J Chemother; 2001 Jun; 13(3):219-34. PubMed ID: 11450879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for immunotherapy in multiple sclerosis.
    Whitaker JN
    Ann Neurol; 1994; 36 Suppl():S103-7. PubMed ID: 8017867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel delivery mechanisms for antigen-specific immunotherapy.
    Neef T; Miller SD
    Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):404-410. PubMed ID: 34101653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New trends in immunosuppression and immunotherapy.
    Jiang S; Lombardi G
    Int Immunopharmacol; 2006 Dec; 6(13-14):1874-8. PubMed ID: 17161339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutics of multiple sclerosis.
    Durelli L
    Acta Neurol (Napoli); 1991 Oct; 13(5):467-75. PubMed ID: 1723242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs in autoimmune diseases.
    Herrmann DB; Bicker U
    Klin Wochenschr; 1990; 68 Suppl 21():15-25. PubMed ID: 2198387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-specific immunotherapies in rheumatic diseases.
    Pozsgay J; Szekanecz Z; Sármay G
    Nat Rev Rheumatol; 2017 Sep; 13(9):525-537. PubMed ID: 28701761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future therapies for myasthenia gravis.
    Yi Q; Lefvert AK
    Drugs Aging; 1997 Aug; 11(2):132-9. PubMed ID: 9259176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The current outlook in the therapy of autoimmune diseases].
    Sebastiani GD; Passiu G
    Ann Ital Med Int; 1992; 7(2):95-101. PubMed ID: 1467130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.